| REBGX | RGLCX | REBGX / RGLCX | |
| Total Expense Ratio | 1.25 | 1.09 | 115% |
| Annual Report Gross Expense Ratio | 1.25 | 1.09 | 115% |
| Fund Existence | 11 years | 14 years | - |
| Gain YTD | 2.921 | 2.957 | 99% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 250 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 7.23B | 7.23B | 100% |
| Annual Yield % from dividends | 0.40 | 0.57 | 70% |
| Returns for 1 year | 16.71 | 16.89 | 99% |
| Returns for 3 years | 49.29 | 50.07 | 98% |
| Returns for 5 years | 18.16 | 19.00 | 96% |
| Returns for 10 years | 116.90 | 119.71 | 98% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GQGIX | 19.05 | 0.29 | +1.55% |
| GQG Partners Emerging Markets EquityInst | |||
| FBDIX | 168.78 | 0.72 | +0.43% |
| Franklin Biotechnology Discovery A | |||
| TRMSX | 22.23 | -0.13 | -0.58% |
| T. Rowe Price Mid-Cap Index I | |||
| TSPTX | 5.39 | -0.06 | -1.10% |
| Transamerica Small Cap Growth I3 | |||
| VCSTX | 40.36 | -0.73 | -1.78% |
| VALIC Company I Science & Technology | |||